Edwards Lifesciences stock heads into the open after a 4.1 percent jump
Published on 09/17/2026 at 05:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences stock closed around USD 89 on the NYSE on September 16, 2026, after rising about 4.1% in that session. The shares moved within a 52-week range reported between roughly USD 72 and USD 96, leaving them toward the upper half of that band at the latest close. The advance contrasted with a decline of about 0.4% in the S&P 500 on September 16, 2026, indicating that the stock outperformed the broader US market on the day.
September 16, 2026 in numbers
Edwards Lifesciences Corp. (ISIN US28176E1082) saw its share price climb to approximately USD 89.28 on September 16, 2026, a gain of 4.1% compared with the prior NYSE close, according to a session wrap from GuruFocus. The same report cited a 52-week trading band from USD 72.30 to USD 96.29, meaning the latest close stood roughly 17% above the 52-week low and about 7% below the 52-week high. In parallel, the S&P 500 closed lower by 0.4% at 7,551.81 on September 16, 2026, as summarized by KRMG, underscoring the stock’s relative strength against the benchmark index.
Intraday, the stock’s move was also noted in a gainers overview that listed Edwards Lifesciences at USD 89.30 with a 4.15% increase on September 16, 2026, highlighting its role among notable US risers that day, per coverage in The Economic Times. Another same-day commentary described a roughly 3.7% rise as short-term investors stepped in after early selling pressure and framed the session as a rebound for the shares, according to Traders Union. Together, these reports point to active trading interest and a decisive move higher in the latest completed session.
Conference appearance in focus today
Today, Edwards Lifesciences is due to present at the Deutsche Bank 2026 Healthcare Summit, an investor event scheduled for September 16, 2026 at 10:00 a.m. EDT, as outlined in a presentation notice on Seeking Alpha. The company’s participation in this healthcare summit gives investors a fresh opportunity to hear management discuss growth priorities and industry trends, and comments from the event may influence sentiment around the stock as trading unfolds today ahead of and after the US opening bell.
